Shanghai (ots/PRNewswire) – Pulnovo Medical Limited, a globally recognized device pioneer in the treatment of pulmonary hypertension (PH) and heart failure (HF), is pleased to announce the successful initiation and enrollment of the first two patients in its global multicenter clinical trial investigating percutaneous denervation of the pulmonary arteries ( PADN) for the treatment of pulmonary hypertension associated with left heart failure. This groundbreaking event took place at the Centro Hospitalar Universitário de Lisboa Central – Hospital de Santa Marta in Portugal and marked the beginning of the introduction of Pulnovo Medical’s innovative products on a global scale.
Under the leadership of Professor Hang Zhang from Nanjing Medical University Affiliated Nanjing Hospital, Prof. Ruben Ramos and his team successfully performed the PADN procedure on two patients. The procedure went smoothly, the equipment was easy to use, and the results were excellent. The Portuguese medical team was impressed by the safe use and efficiency of the PADN technology, as the long-term data had already suggested. The clinical parameters showed promising results when using PADN technology. The overall structure of the products and high-precision algorithm control ensured stable energy delivery and effective surgical results.
Present. Ruben Ramos said: “PADN technology shows great potential in the treatment of pulmonary hypertension associated with left heart failure. We are pleased to be the first in Europe to take part in this global clinical trial. Our team is confident in this project and looks forward to offering more treatment options to European patients with pulmonary hypertension through this study. PADN is not only a new treatment method, but also brings new hope for patients suffering from pulmonary hypertension.”
Jessie Lian, CEO von Pulnovo Medical, said: “The global multicenter PADN clinical trial is one of our key projects addressing innovative treatment technologies in the cardiovascular field. As a new treatment method, PADN has enormous potential and good prospects. The postoperative results of the first use of PADN abroad demonstrate the universal applicability of the method. In the future, we will continue to resolutely advance our global business and continuously promote the teaching and learning of PADN technology.”
Cynthia Chen, CEO of Pulnovo Medical, said: “We are proud to have successfully completed the first recruitment into PADN’s European multicenter clinical trial in Portugal. This step will support the global spread of our technology. We will continue to advance the global use of PADN so that even more patients can benefit from this innovative therapy.”
Questions & Contact:
chenhan@pulnovomed.com